Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Jump to section
Related Articles
Cited By...
- Safety, Dosimetry, and Feasibility of [68Ga]Ga-PSMA-R2 as an Imaging Agent in Patients with Biochemical Recurrence or Metastatic Prostate Cancer
- Development of a 213Bi-Labeled Pyridyl Benzofuran for Targeted {alpha}-Therapy of Amyloid-{beta} Aggregates
- Deescalated 225Ac-PSMA-617 Versus 177Lu/225Ac-PSMA-617 Cocktail Therapy: A Single-Center Retrospective Analysis of 233 Patients
- Development and Preclinical Evaluation of [211At]PSAt-3-Ga: An Inhibitor for Targeted {alpha}-Therapy of Prostate Cancer
- Current Status of Prostate-specific Membrane Antigen-targeted Alpha Radioligand Therapy in Prostate Cancer
- Tandem Isotope Therapy with 225Ac- and 177Lu-PSMA-617 in a Murine Model of Prostate Cancer
- Prediction of Response to 177Lu-PSMA Therapy Based on Tumor-to-Kidney Ratio on Pretherapeutic PSMA PET/CT and Posttherapeutic Tumor-Dose Evaluation in mCRPC
- Optimized Methods for the Production of High-Purity 203Pb Using Electroplated Thallium Targets
- Pre-clinical Evaluation of Biomarkers for Early Detection of Nephrotoxicity Following Alpha-particle Radioligand Therapy
- Tumor Control Probability and Small-Scale Monte Carlo Dosimetry: Effects of Heterogenous Intratumoral Activity Distribution in Radiopharmaceutical Therapy
- Clinical Experience with [225Ac]Ac-PSMA Treatment in Patients with [177Lu]Lu-PSMA-Refractory Metastatic Castration-Resistant Prostate Cancer
- Dual-Time-Point Posttherapy 177Lu-PSMA-617 SPECT/CT Describes the Uptake Kinetics of mCRPC Lesions and Prognosticates Patients Outcome
- Signaling Network Response to {alpha}-Particle-Targeted Therapy with the 225Ac-Labeled Minigastrin Analog 225Ac-PP-F11N Reveals the Radiosensitizing Potential of Histone Deacetylase Inhibitors
- Evaluation of 134Ce/134La as a PET Imaging Theranostic Pair for 225Ac {alpha}-Radiotherapeutics
- Clinical Translation of Targeted {alpha}-Therapy: An Evolution or a Revolution?
- Dosimetric Variability Across a Library of Computational Tumor Phantoms
- Targeted {alpha}-Therapy Using 225Ac Radiolabeled Single-Domain Antibodies Induces Antigen-Specific Immune Responses and Instills Immunomodulation Both Systemically and at the Tumor Microenvironment
- Targeted {alpha}-Therapy Using 225Ac Radiolabeled Single-Domain Antibodies Induces Antigen-Specific Immune Responses and Instills Immunomodulation Both Systemically and at the Tumor Microenvironment
- Clinical Translation of Targeted {alpha}-Therapy: An Evolution or a Revolution?
- 225Ac-MACROPATATE: A Novel {alpha}-Particle Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors
- Dosimetry in Radiopharmaceutical Therapy
- mCRPC Patients Receiving 225Ac-PSMA-617 Therapy in the Post-Androgen Deprivation Therapy Setting: Response to Treatment and Survival Analysis
- Profound immunomodulatory effects of 225Ac-NM600 drive enhanced anti-tumor response in prostate cancer
- Pretargeting: A Path Forward for Radioimmunotherapy
- Combination of Carriers with Complementary Intratumoral Microdistributions of Delivered {alpha}-Particles May Realize the Promise for 225Ac in Large, Solid Tumors
- Prostate-Specific Membrane Antigen Radioligand Therapy Using 177Lu-PSMA I&T and 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution, and Dosimetry
- First In Vivo and Phantom Imaging of Cyclotron-Produced 133La as a Theranostic Radionuclide for 225Ac and 135La
- [18F]-Labeled PARP-1 PET Imaging of PSMA Targeted Alpha Particle Radiotherapy Response
- The History of Prostate-Specific Membrane Antigen as a Theranostic Target in Prostate Cancer: The Cornerstone Role of the Prostate Cancer Foundation
- An Improved 211At-Labeled Agent for PSMA-Targeted {alpha}-Therapy
- Harnessing {alpha}-Emitting Radionuclides for Therapy: Radiolabeling Method Review
- The Impact of Monosodium Glutamate on 68Ga-PSMA-11 Biodistribution in Men with Prostate Cancer: A Prospective Randomized, Controlled Imaging Study
- Darolutamide Potentiates the Antitumor Efficacy of a PSMA-targeted Thorium-227 Conjugate by a Dual Mode of Action in Prostate Cancer Models
- Cyclotron-Produced 132La as a PET Imaging Surrogate for Therapeutic 225Ac
- First Clinical Results for PSMA-Targeted {alpha}-Therapy Using 225Ac-PSMA-I&T in Advanced-mCRPC Patients
- PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman Primates
- Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET
- The Future of Nuclear Medicine, Molecular Imaging, and Theranostics
- Oncology-Inspired Treatment Options for COVID-19
- Harnessing 64Cu/67Cu for a theranostic approach to pretargeted radioimmunotherapy
- PSA-targeted Alpha-, Beta- and Positron Emitting Immuno-Theranostics in Murine Prostate Cancer Models and Non-Human Primates
- 177Lu-NM600 Targeted Radionuclide Therapy Extends Survival in Syngeneic Murine Models of Triple-Negative Breast Cancer
- A simple strategy to reduce the salivary gland and kidney uptake of PSMA targeting small molecule radiopharmaceuticals
- Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer
- Theranostics Targeting Fibroblast Activation Protein in the Tumor Stroma: 64Cu- and 225Ac-Labeled FAPI-04 in Pancreatic Cancer Xenograft Mouse Models
- Theranostics: Leveraging Molecular Imaging and Therapy to Impact Patient Management and Secure the Future of Nuclear Medicine
- Impact of 18F-PSMA-1007 Uptake in Prostate Cancer Using Different Peptide Concentrations: Preclinical PET/CT Study on Mice
- First Clinicopathologic Evidence of a Non-PSMA-Related Uptake Mechanism for 68Ga-PSMA-11 in Salivary Glands
- 3D-printed automation for optimized PET radiochemistry
- Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine
- A Single Dose of 225Ac-RPS-074 Induces a Complete Tumor Response in an LNCaP Xenograft Model
- Albumin-Binding PSMA Ligands: Implications for Expanding the Therapeutic Window
- PSMA Expression in the Hi-Myc Model; Extended Utility of a Representative Model of Prostate Adenocarcinoma for Biological Insight and as a Drug Discovery Tool
- Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes
- Leveraging Bioorthogonal Click Chemistry to Improve 225Ac-Radioimmunotherapy of Pancreatic Ductal Adenocarcinoma
- Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer
- Combined VLA-4-Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma
- The Relevance of Dosimetry in Precision Medicine
- A Gallium-67/68-Labeled Antibody Fragment for Immuno-SPECT/PET Shows Low Renal Radioactivity Without Loss of Tumor Uptake
- {alpha}-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies--Part 2
- Penetrating the Barriers to Successful {alpha}-Radioimmunotherapy
- {alpha}-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies--Part 1
- Treatment of Advanced Prostate Cancer--A Review of Current Therapies and Future Promise
- Targeted {alpha}-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control
- Molecular Imaging of Prostate Cancer: Choosing the Right Agent
- Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors
- Targeted {alpha}-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding
- Molecular radiotheragnostics in prostate cancer
- Dual-Target Binding Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer
- Iodine Symporter Targeting with 124I/131I Theranostics
- Therapeutic Radiometals Beyond 177Lu and 90Y: Production and Application of Promising {alpha}-Particle, {beta}--Particle, and Auger Electron Emitters
- Glu-Ureido-Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers
- Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy
- 177Lu-PSMA Radioligand Therapy for Prostate Cancer
- Acceleration of PSMA-Targeted Theranostics to the Clinic: Can Common Sense Prevail?
- Why Targeting of PSMA Is a Valuable Addition to the Management of Castration-Resistant Prostate Cancer: The Urologists Point of View
- The Future of Radioligand Therapy: {alpha}, {beta}, or Both?
- {alpha}- Versus {beta}-Emitting Radionuclides for Pretargeted Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colon Cancer Xenografts